Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.

Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM.

Anticancer Drugs. 2011 Sep;22(8):719-31. doi: 10.1097/CAD.0b013e328346f3b4.

PMID:
21666438
2.

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.

Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.

Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. Epub 2005 Jun 10.

PMID:
15947928
3.

Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB.

Int J Cancer. 2010 Jul 15;127(2):257-68. doi: 10.1002/ijc.25041. Erratum in: Int J Cancer. 2015 Dec 15;137(12):E21.

4.

Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.

Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP.

Cancer Res. 2009 Jul 15;69(14):5876-84. doi: 10.1158/0008-5472.CAN-09-0536.

5.

Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.

Paik WH, Ryu JK, Jeong KS, Park JM, Song BJ, Lee SH, Kim YT, Yoon YB.

World J Gastroenterol. 2014 Jul 14;20(26):8545-57. doi: 10.3748/wjg.v20.i26.8545.

6.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A.

Mol Cancer Ther. 2015 Jul;14(7):1570-81. doi: 10.1158/1535-7163.MCT-15-0104. Epub 2015 May 1.

7.

Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Int J Cancer. 2009 Aug 15;125(4):942-51. doi: 10.1002/ijc.24424.

8.

Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.

Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ.

Int J Oncol. 2011 Nov;39(5):1123-31. doi: 10.3892/ijo.2011.1115. Epub 2011 Jul 6.

PMID:
21743963
9.

Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.

Guo HC, Bu HQ, Luo J, Wei WT, Liu DL, Chen H, Tong HF, Wang ZH, Wu HY, Li HH, Zuo MM, Li W, Lin SZ.

Int J Oncol. 2012 Jun;40(6):1849-57. doi: 10.3892/ijo.2012.1389. Epub 2012 Feb 29.

PMID:
22378302
10.

Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.

11.

Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.

Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA.

Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. Epub 2007 Sep 28.

PMID:
17901954
12.

Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.

Ahn DW, Seo JK, Lee SH, Hwang JH, Lee JK, Ryu JK, Kim YT, Yoon YB.

Pancreas. 2012 Oct;41(7):1048-57. doi: 10.1097/MPA.0b013e318249d62e.

PMID:
22513291
13.

Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Gao CC, Xu XL, Li F, Gong BG, Liu S, Cui YQ, Sun HC, Xu PY, Zheng YM, Jiang H.

Tumour Biol. 2016 Jun;37(6):7555-64. doi: 10.1007/s13277-015-4641-2. Epub 2015 Dec 18.

PMID:
26684804
14.

Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.

Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB.

Int J Cancer. 2012 Aug 1;131(3):E292-303. doi: 10.1002/ijc.26442. Epub 2011 Nov 9.

15.

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.

J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300.

PMID:
17114015
16.
17.

Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.

Wang F, Tian X, Zhang Z, Ma Y, Xie X, Liang J, Yang C, Yang Y.

Int J Cancer. 2018 May 1;142(9):1938-1951. doi: 10.1002/ijc.31211. Epub 2018 Jan 4.

18.

OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.

Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.

Oncotarget. 2015 Sep 22;6(28):26230-41. doi: 10.18632/oncotarget.4579.

19.

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.

20.

Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

HPB (Oxford). 2011 Sep;13(9):597-604. doi: 10.1111/j.1477-2574.2011.00333.x. Epub 2011 Jun 7.

Supplemental Content

Support Center